Ruotsalainen, J J
Kaikkonen, M U
Niittykoski, M
Martikainen, M W
Lemay, C G
Cox, J
De Silva, N S
Kus, A
Falls, T J
Diallo, J-S
Le Boeuf, F
Bell, J C
Ylä-Herttuala, S
Hinkkanen, A E
Vähä-Koskela, M J
Article History
Received: 7 March 2014
Revised: 11 June 2014
Accepted: 6 August 2014
First Online: 18 September 2014
Competing interests
: John Bell is co-founder of Jennerex Biotherapeutics and sits on the Board of Directors. The remaining authors declare no conflict of interest.